Results 211 to 220 of about 453,120 (310)

A Collaborative Model to Meet the Wellness Needs of Graduate Medical Education Programs. [PDF]

J Grad Med Educ
Furnari M, Hollander-Rodriguez J, Rea M.
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

HybridSense-LLM: A Structured Multimodal Framework for Large-Language-Model-Based Wellness Prediction from Wearable Sensors with Contextual Self-Reports. [PDF]

Bioengineering (Basel)
Yu CH, Masum M.
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

WHOOP, There It Is: Lessons From WHOOP's FDA Warning Letter.

J Med Internet Res
Karow B.
europepmc   +1 more source

Use of implementation science methods to design Wellness Hub, a responsive program to address long-term care and retirement homes' challenges during the COVID-19 pandemic. [PDF]

BMC Health Serv Res
Fahim C, Quinn de Launay K, Bach V, Firman J, Gapare CR, Gruppuso V, Hassan AT, Mrazovac A, Odunuga T, Paul N, Strifler L, Takaoka A, Togo E, Gao HJC, Boyd JM, Straus SE.   +15 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Wellness-enhanced contingency management for stimulant use: A formative qualitative study. [PDF]

Digit Health
Deshais MA, Norton L, Tkac V, Digioia-Laird V, Swarbrick M.   +4 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Patterns and Characteristics of Mobile App Use to Promote Wellness and Manage Illness: Cross-Sectional Study. [PDF]

J Med Internet Res
Gulec H, Smahel D, Huang Y.
europepmc   +1 more source